Silence Therapeutics plc
SLN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479615
No open-market purchases or sales by Silence Therapeutics plc insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $236.2M in total; no superinvestor holds it.
Other share classesSLNCF
Q4 2022 vs. Q3 2022
How the institutions holding Silence Therapeutics plc changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 29 | 27 | −2 |
| Shares | 18.7M | 18.6M | −19.7K (−0.1%) |
| Value | $183.4M | $275.7M | +$92.4M (+50.4%) |
New holders (2)
Institutions that held Silence Therapeutics plc at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| M28 Capital Management LP | 145,900 | $2.22M | 2.12% |
| Schonfeld Strategic Advisors LLC | 29,500 | $449.9K | 0.00% |
Sold out (4)
Institutions that held Silence Therapeutics plc at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| UBS Oconnor LLC | 79,636 | $786.0K |
| Great Point Partners LLC | 68,915 | $692.0K |
| Citadel Advisors LLC | 22,851 | $226.0K |
| Cubist Systematic Strategies, LLC | 500 | $5.00K |